AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $212.49 billion. The enterprise value is $235.15 billion.
| Market Cap | 212.49B |
| Enterprise Value | 235.15B |
Important Dates
The next confirmed earnings date is Thursday, April 25, 2024, before market open.
| Earnings Date | Apr 25, 2024 |
| Ex-Dividend Date | Feb 22, 2024 |
Share Statistics
AstraZeneca has 3.10 billion shares outstanding.
| Shares Outstanding | 3.10B |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 16.81% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 35.79 and the forward PE ratio is 16.31. AstraZeneca's PEG ratio is 0.89.
| PE Ratio | 35.79 |
| Forward PE | 16.31 |
| PS Ratio | 4.64 |
| Forward PS | 4.06 |
| PB Ratio | 5.43 |
| P/FCF Ratio | 23.31 |
| PEG Ratio | 0.89 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.91, with an EV/FCF ratio of 25.80.
| EV / Earnings | 39.49 |
| EV / Sales | 5.13 |
| EV / EBITDA | 16.91 |
| EV / EBIT | 27.60 |
| EV / FCF | 25.80 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.73.
| Current Ratio | 0.82 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 2.06 |
| Debt / FCF | 3.14 |
| Interest Coverage | 5.24 |
Financial Efficiency
Return on equity (ROE) is 15.90% and return on invested capital (ROIC) is 10.45%.
| Return on Equity (ROE) | 15.90% |
| Return on Assets (ROA) | 6.10% |
| Return on Capital (ROIC) | 10.45% |
| Revenue Per Employee | $509,577 |
| Profits Per Employee | $66,240 |
| Employee Count | 89,900 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 1.63 |
Taxes
In the past 12 months, AstraZeneca has paid $938.00 million in taxes.
| Income Tax | 938.00M |
| Effective Tax Rate | 13.61% |
Stock Price Statistics
The stock price has decreased by -8.40% in the last 52 weeks. The beta is 0.19, so AstraZeneca's price volatility has been lower than the market average.
| Beta (1Y) | 0.19 |
| 52-Week Price Change | -8.40% |
| 50-Day Moving Average | 66.12 |
| 200-Day Moving Average | 66.62 |
| Relative Strength Index (RSI) | 58.36 |
| Average Volume (30 Days) | 6,269,330 |
Short Selling Information
| Short Interest | 7.66M |
| Short Previous Month | 10.48M |
| Short % of Shares Out | 0.27% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.61 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $45.81 billion and earned $5.96 billion in profits. Earnings per share was $1.91.
| Revenue | 45.81B |
| Gross Profit | 37.54B |
| Operating Income | 8.19B |
| Pretax Income | 6.89B |
| Net Income | 5.96B |
| EBITDA | 13.91B |
| EBIT | 8.52B |
| Earnings Per Share (EPS) | $1.91 |
Balance Sheet
The company has $5.96 billion in cash and $28.62 billion in debt, giving a net cash position of -$22.66 billion or -$7.31 per share.
| Cash & Cash Equivalents | 5.96B |
| Total Debt | 28.62B |
| Net Cash | -22.66B |
| Net Cash Per Share | -$7.31 |
| Equity / Book Value | 39.14B |
| Book Value Per Share | 12.63 |
| Working Capital | -5.49B |
Cash Flow
In the last 12 months, operating cash flow was $10.35 billion and capital expenditures -$1.23 billion, giving a free cash flow of $9.12 billion.
| Operating Cash Flow | 10.35B |
| Capital Expenditures | -1.23B |
| Free Cash Flow | 9.12B |
| FCF Per Share | $2.94 |
Margins
Gross margin is 81.95%, with operating and profit margins of 17.88% and 13.00%.
| Gross Margin | 81.95% |
| Operating Margin | 17.88% |
| Pretax Margin | 15.05% |
| Profit Margin | 13.00% |
| EBITDA Margin | 30.36% |
| EBIT Margin | 18.60% |
| FCF Margin | 19.90% |
Dividends & Yields
This stock pays an annual dividend of $1.45, which amounts to a dividend yield of 2.12%.
| Dividend Per Share | $1.45 |
| Dividend Yield | 2.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 76.12% |
| Buyback Yield | -0.13% |
| Shareholder Yield | 1.99% |
| Earnings Yield | 2.80% |
| FCF Yield | 4.29% |
Analyst Forecast
The average price target for AstraZeneca is $81.67, which is 19.14% higher than the current price. The consensus rating is "Buy".
| Price Target | $81.67 |
| Price Target Difference | 19.14% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 6.69% |
| EPS Growth Forecast (5Y) | 25.82% |
Stock Splits
The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
AstraZeneca has an Altman Z-Score of 2.74 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.74 |
| Piotroski F-Score | 7 |